|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2007; 49:1733-1739, doi:10.1016/j.jacc.2006.10.081
(Published online 30 March 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,*
* René Descartes University, Paris, France
Georges Pompidou Hospital, Paris, France
Department of Cardiology, Bichat University Hospital, Paris, France
Department of Cardiology, Centre Hospitalier Universitaire de Lariboisière, Paris, France
Hospitalier de Rene Dubos, Pontoise, France
|| Centre Hospitalier Universitaire de Nantes, Nantes, France
¶ Centre Hospitalier Universitaire de Rennes, Rennes, France
# Hopital Saint Luc Lyon, Lyon, France
** Department of Cardiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Centre Hospitalier Universitaire de Dijon, Dijon, France
Department of Cardiology, Centre Hospitalier Universitaire de Vandoeuvre Les Nancy, Vandoeuvre Les Nancy, France.
Manuscript received September 12, 2006; revised manuscript received October 10, 2006, accepted October 22, 2006.
* Reprint requests and correspondence: Dr. Patrick Jourdain, Hopital de Pontoise, CH Rene Dubos, Heart Failure Department, 6 Avenue de France, Pontoise, 95301 France. (Email: patrick.jourdain{at}ch-pontoise.fr).
Objectives: The aim of this multicenter study was to evaluate the prognostic impact of a therapeutic strategy using plasma brain natriuretic peptide (BNP) levels.
Background: The prognosis of chronic heart failure (CHF) remains poor, even among patients treated in specialized departments.
Methods: A total of 220 New York Heart Association functional class II to III patients considered optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists were randomized to medical treatment according to either current guidelines (clinical group) or a goal of decreasing BNP plasma levels <100 pg/ml (BNP group). Outpatient visits were scheduled every month for 3 months, then every 3 months. The primary combined end point was CHF-related death or hospital stay for CHF.
Results: Both groups were similar for baseline clinical and biological characteristics. Left ventricular ejection fraction was slightly lower in the BNP group than in the clinical group (29.9 ± 7.7% vs. 31.8 ± 8.4%, p = 0.05). At the end of the first 3 months, all types of drugs were changed more frequently in the BNP group. Mean dosages of ACEIs and beta-blockers were significantly higher in the BNP group (p < 0.05), whereas the mean increase in furosemide dosage was similar in both groups. During follow-up (median 15 months), significantly fewer patients reached the combined end point in the BNP group (24% vs. 52%, p < 0.001).
Conclusions: In optimally treated CHF patients, a BNP-guided strategy reduced the risk of CHF-related death or hospital stay for CHF. The result was mainly obtained through an increase in ACEI and beta-blocker dosages.
| ||||||||
This article has been cited by other articles:
|
|
 |
|
  D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur. Heart J., July 8, 2008; (2008) ehn315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishii, T. Inomata, H. Takehana, T. Naruke, T. Yanagisawa, M. Moriguchi, S. Takeda, and T. Izumi Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2329 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mills Learning to use a biomarker. More about B-type natriuretic peptide. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2336 - 2338. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.V. McMurray, B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, D. L. Keefe, J. Ford, A. Verma, J. Lewsey, and for the Aliskiren Observation of Heart Failure Tre Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure CIRCULATION: HEART FAILURE, May 1, 2008; 1(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W Yip B-type natriuretic peptide: a treatment, not a diagnostic marker Heart, May 1, 2008; 94(5): 542 - 544. [Full Text] [PDF]
|
|
|
|
|
|
I. Squire Assessing prognosis in heart failure: you can see a lot if you look, but more if you look again ... ... ... Eur. Heart J., April 2, 2008; 29(8): 959 - 960. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Pascual-Figal, M. Domingo, T. Casas, I. Gich, J. Ordonez-Llanos, P. Martinez, J. Cinca, M. Valdes, J. L. Januzzi, and A. Bayes-Genis Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients Eur. Heart J., April 2, 2008; 29(8): 1011 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Teerlink Learning the points of COMPASS-HF: assessing implantable hemodynamic monitoring in heart failure patients. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1080 - 1082. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jourdain, G. Jondeau, and Y. Juilliere Reply J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2098 - 2099. [Full Text] [PDF]
|
|
|
|
|
|
U. C. Hoppe Plasma Brain Natriuretic Peptide-Guided Therapy Not Yet Justified J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2097 - 2098. [Full Text] [PDF]
|
|
|
|
|
|
A. Maisel Biomarkers in Heart Failure: Does Prognostic Utility Translate to Clinical Futility? J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1061 - 1063. [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]
|
|
|
|
 |
|
 B-type Natriuretic Peptide: The North Star of HF Treatment? Journal Watch Cardiology, April 25, 2007; 2007(425): 2 - 2. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
